Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
mBio ; 11(2)2020 04 14.
Article in English | MEDLINE | ID: mdl-32291300

ABSTRACT

Burkholderia pseudomallei, the founding member of the B. pseudomallei complex (Bpc), is a biothreat agent and causes melioidosis, a disease whose treatment mainly relies on ceftazidime and meropenem. The concern is that B. pseudomallei could enhance its drug resistance repertoire by the acquisition of DNA from resistant near-neighbor species. Burkholderia ubonensis, a member of the B. cepacia complex (Bcc), is commonly coisolated from environments where B. pseudomallei is present. Unlike B. pseudomallei, in which significant primary carbapenem resistance is rare, it is not uncommon in B. ubonensis, but the underlying mechanisms are unknown. We established that carbapenem resistance in B. ubonensis is due to an inducible class A PenB ß-lactamase, as has been shown for other Bcc bacteria. Inducibility is not sufficient for high-level resistance but also requires other determinants, such as a PenB that is more robust than that present in susceptible isolates, as well as other resistance factors. Curiously and diagnostic for the two complexes, both Bpc and Bcc bacteria contain distinct annotated PenA class A ß-lactamases. However, the protein from Bcc bacteria is missing its essential active-site serine and, therefore, is not a ß-lactamase. Regulated expression of a transcriptional penB'-lacZ (ß-galactosidase) fusion in the B. pseudomallei surrogate B. thailandensis confirms that although Bpc bacteria lack an inducible ß-lactamase, they contain the components required for responding to aberrant peptidoglycan synthesis resulting from ß-lactam challenge. Understanding the diversity of antimicrobial resistance in Burkholderia species is informative about how the challenges arising from potential resistance transfer between them can be met.IMPORTANCEBurkholderia pseudomallei causes melioidosis, a tropical disease that is highly fatal if not properly treated. Our data show that, in contrast to B. pseudomallei, B. ubonensis ß-lactam resistance is fundamentally different because intrinsic resistance is mediated by an inducible class A ß-lactamase. This includes resistance to carbapenems. Our work demonstrates that studies with near-neighbor species are informative about the diversity of antimicrobial resistance in Burkholderia and can also provide clues about the potential of resistance transfer between bacteria inhabiting the same environment. Knowledge about potential adverse challenges resulting from the horizontal transfer of resistance genes between members of the two complexes enables the design of effective countermeasures.


Subject(s)
Anti-Bacterial Agents/pharmacology , Burkholderia cepacia complex/enzymology , Burkholderia pseudomallei/enzymology , Burkholderia/drug effects , Meropenem/pharmacology , beta-Lactam Resistance/genetics , beta-Lactamases/genetics , Burkholderia/enzymology , Burkholderia cepacia complex/genetics , Burkholderia pseudomallei/genetics , Humans , Microbial Sensitivity Tests , beta-Lactamases/classification
2.
Curr Microbiol ; 76(4): 485-494, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30783798

ABSTRACT

Burkholderia contaminans is a member of the Burkholderia cepacia complex (Bcc), a pathogen with increasing prevalence among cystic fibrosis (CF) patients and the cause of numerous outbreaks due to the use of contaminated commercial products. The antibiotic resistance determinants, particularly ß-lactamases, have been poorly studied in this species. In this work, we explored the whole genome sequence (WGS) of a B. contaminans isolate (FFH 2055) and detected four putative ß-lactamase-encoding genes. In general, these genes have more than 93% identity with ß-lactamase genes found in other Bcc species. Two ß-lactamases, a class A (Pen-like, suggested name PenO) and a class D (OXA-like), were further analyzed and characterized. Amino acid sequence comparison showed that Pen-like has 82% and 67% identity with B. multivorans PenA and B. pseudomallei PenI, respectively, while OXA-like displayed strong homology with class D enzymes within the Bcc, but only 22-44% identity with available structures from the OXA family. PCR reactions designed to study the presence of these two genes revealed a heterogeneous distribution among clinical and industrial B. contaminans isolates. Lastly, blaPenO gene was cloned and expressed into E. coli to investigate the antibiotic resistance profile and confers an extended-spectrum ß-lactamase (ESBL) phenotype. These results provide insight into the presence of ß-lactamases in B. contaminans, suggesting they play a role in antibiotic resistance of these bacteria.


Subject(s)
Bacterial Proteins/genetics , Burkholderia cepacia complex/enzymology , Burkholderia cepacia complex/genetics , Genome, Bacterial/genetics , beta-Lactamases/genetics , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Burkholderia Infections/microbiology , Burkholderia cepacia complex/drug effects , Cystic Fibrosis/microbiology , Drug Resistance, Multiple, Bacterial , Escherichia coli/drug effects , Escherichia coli/genetics , Humans , Microbial Sensitivity Tests , Models, Molecular , Sequence Homology, Amino Acid , beta-Lactamases/chemistry , beta-Lactamases/metabolism
3.
ACS Infect Dis ; 3(7): 502-511, 2017 07 14.
Article in English | MEDLINE | ID: mdl-28264560

ABSTRACT

Burkholderia multivorans is a significant health threat to persons with cystic fibrosis (CF). Infections are difficult to treat as this pathogen is inherently resistant to multiple antibiotics. Susceptibility testing of isolates obtained from CF respiratory cultures revealed that single agents selected from different antibiotic classes were unable to inhibit growth. However, all isolates were found to be susceptible to ceftazidime when combined with the novel non-ß-lactam ß-lactamase inhibitor, avibactam (all minimum inhibitor concentrations (MICs) were ≤8 mg/L of ceftazidime and 4 mg/L of avibactam). Furthermore, a major ß-lactam resistance determinant expressed in B. multivorans, the class A carbapenemase, PenA was readily inhibited by avibactam with a high k2/K of (2 ± 1) × 106 µM-1 s-1 and a slow koff of (2 ± 1) × 10-3 s-1. Mass spectrometry revealed that avibactam formed a stable complex with PenA for up to 24 h and that avibactam recyclized off of PenA, re-forming the active compound. Crystallographic analysis of PenA-avibactam revealed several interactions that stabilized the acyl-enzyme complex. The deacylation water molecule possessed decreased nucleophilicity, preventing decarbamylation. In addition, the hydrogen-bonding interactions with Lys-73 were suggestive of a protonated state. Thus, Lys-73 was unlikely to abstract a proton from Ser-130 to initiate recyclization. Using Galleria mellonella larvae as a model for infection, ceftazidime-avibactam was shown to significantly (p < 0.001) improve survival of larvae infected with B. multivorans. To further support the translational impact, the ceftazidime-avibactam combination was evaluated using susceptibility testing against other strains of Burkholderia spp. that commonly infect individuals with CF, and 90% of the isolates were susceptible to the combination. In summary, ceftazidime-avibactam may serve as a preferred therapy for people that have CF and develop Burkholderia spp. infections and should be considered for clinical trials.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azabicyclo Compounds/pharmacology , Burkholderia Infections/microbiology , Burkholderia cepacia complex/drug effects , Ceftazidime/pharmacology , Protons , Animals , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Burkholderia cepacia complex/enzymology , Burkholderia cepacia complex/growth & development , Burkholderia cepacia complex/isolation & purification , Cystic Fibrosis/microbiology , Drug Synergism , Drug Therapy, Combination , Humans , Hydrogen Bonding , Larva/drug effects , Larva/microbiology , Microbial Sensitivity Tests , Moths/drug effects , Moths/microbiology , Opportunistic Infections/microbiology , Protein Binding , beta-Lactam Resistance/drug effects , beta-Lactamases/metabolism
4.
Environ Microbiol Rep ; 7(2): 180-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25294803

ABSTRACT

The Burkholderia cepacia complex (Bcc) is a group of Gram-negative bacilli that are ubiquitous in the environment and have emerged over the past 30 years as opportunistic pathogens in immunocompromised populations, specifically individuals with cystic fibrosis (CF) and chronic granulomatous disease. This complex of at least 18 distinct species is phenotypically and genetically diverse. One phenotype observed in a subset of Burkholderia cenocepacia (a prominent Bcc pathogen) isolates is the ability to produce a melanin-like pigment. Melanins have antioxidant properties and have been shown to act as virulence factors allowing pathogens to resist killing by the host immune system. The melanin-like pigment expressed by B. cenocepacia is produced through tyrosine catabolism, specifically through the autoxidation and polymerization of homogentisate. Burkholderia cenocepacia J2315 is a CF clinical isolate that displays a pigmented phenotype when grown under normal laboratory conditions. We examined the amino acid sequences of critical enzymes in the melanin synthesis pathway in pigmented and non-pigmented Bcc isolates, and found that an amino acid substitution of glycine for arginine at amino acid 378 in homogentisate 1,2-dioxygenase correlated with pigment production; we identify this as one mechanism for expression of pigment in Bcc isolates.


Subject(s)
Amino Acid Substitution , Burkholderia cepacia complex/chemistry , Burkholderia cepacia complex/enzymology , Homogentisate 1,2-Dioxygenase/genetics , Homogentisate 1,2-Dioxygenase/metabolism , Pigments, Biological/analysis , Burkholderia Infections/microbiology , Burkholderia cepacia complex/growth & development , Burkholderia cepacia complex/isolation & purification , Cystic Fibrosis/complications , Humans , Mutant Proteins/genetics , Mutant Proteins/metabolism
5.
Infect Immun ; 83(2): 812-21, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25486990

ABSTRACT

Bacterial tyrosine kinases and their cognate protein tyrosine phosphatases are best known for regulating the biosynthesis of polysaccharides. Moreover, their roles in the stress response, DNA metabolism, cell division, and virulence have also been documented. The aim of this study was to investigate the pathogenicity and potential mechanisms of virulence dependent on the tyrosine kinase BceF and phosphotyrosine phosphatase BceD of the cystic fibrosis opportunistic pathogen Burkholderia contaminans IST408. The insertion mutants bceD::Tp and bceF::Tp showed similar attenuation of adhesion and invasion of the cystic fibrosis lung epithelial cell line CFBE41o- compared to the parental strain B. contaminans IST408. In the absence of bceD or bceF genes, B. contaminans also showed a reduction in the ability to translocate across polarized epithelial cell monolayers, demonstrated by a higher transepithelial electrical resistance, reduced flux of fluorescein isothiocyanate-labeled bovine serum albumin, and higher levels of tight junction proteins ZO-1, occludin, and claudin-1 present in monolayers exposed to these bacterial mutants. Furthermore, bceD::Tp and bceF::Tp mutants induced lower levels of interleukin-6 (IL-6) and IL-8 release than the parental strain. In conclusion, although the mechanisms of pathogenicity dependent on BceD and BceF are not understood, these proteins contribute to the virulence of Burkholderia by enhancement of cell attachment and invasion, disruption of epithelial integrity, and modulation of the proinflammatory response.


Subject(s)
Burkholderia cepacia complex/pathogenicity , Cystic Fibrosis/microbiology , Lung/microbiology , Protein Tyrosine Phosphatases/physiology , Protein-Tyrosine Kinases/physiology , Respiratory Mucosa/microbiology , Virulence Factors/genetics , Albumins/metabolism , Anti-Bacterial Agents/pharmacology , Bacterial Adhesion , Burkholderia Infections/microbiology , Burkholderia Infections/pathology , Burkholderia cepacia complex/enzymology , Burkholderia cepacia complex/genetics , Cell Line , Ciprofloxacin/pharmacology , Claudin-1/biosynthesis , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Electric Impedance , Humans , Inflammation/immunology , Interleukin-6/biosynthesis , Interleukin-6/metabolism , Interleukin-8/biosynthesis , Interleukin-8/metabolism , Membrane Potentials , Mutation , Occludin/biosynthesis , Protein Transport , Protein Tyrosine Phosphatases/genetics , Protein-Tyrosine Kinases/genetics , Tight Junctions/pathology , Zonula Occludens-1 Protein/biosynthesis
6.
PLoS One ; 8(2): e56902, 2013.
Article in English | MEDLINE | ID: mdl-23460819

ABSTRACT

This work reports the biochemical and functional analysis of the Burkholderia cenocepacia J2315 bceN gene, encoding a protein with GDP-D-mannose 4,6-dehydratase enzyme activity (E.C.4.2.1.47). Data presented indicate that the protein is active when in the tetrameric form, catalyzing the conversion of GDP-D-mannose into GDP-4-keto-6-deoxy-D-mannose. This sugar nucleotide is the intermediary necessary for the biosynthesis of GDP-D-rhamnose, one of the sugar residues of cepacian, the major exopolysaccharide produced by environmental and human, animal and plant pathogenic isolates of the Burkholderia cepacia complex species. Vmax and Km values of 1.5±0.2 µmol.min(-1).mg(-1) and 1024±123 µM, respectively, were obtained from the kinetic characterization of the B. cenocepacia J2315 BceN protein by NMR spectroscopy, at 25°C and in the presence of 1 mol MgCl2 per mol of protein. The enzyme activity was strongly inhibited by the substrate, with an estimated Ki of 2913±350 µM. The lack of a functional bceN gene in a mutant derived from B. cepacia IST408 slightly reduced cepacian production. However, in the B. multivorans ATCC17616 with bceN as the single gene in its genome with predicted GMD activity, a bceN mutant did not produce cepacian, indicating that this gene product is required for cepacian biosynthesis.


Subject(s)
Burkholderia cepacia complex/enzymology , Burkholderia cepacia complex/genetics , Genes, Bacterial/genetics , Hydro-Lyases/genetics , Hydro-Lyases/metabolism , Amino Acid Sequence , Biocatalysis , Guanosine Diphosphate Mannose/metabolism , Histidine/metabolism , Humans , Hydro-Lyases/chemistry , Kinetics , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Sequence Data , Mutation/genetics , Oligopeptides/metabolism , Polysaccharides, Bacterial/biosynthesis , Protein Multimerization , Sequence Analysis, DNA , Substrate Specificity
7.
J Antimicrob Chemother ; 65(11): 2376-81, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20801783

ABSTRACT

BACKGROUND: NXL104 potentiates ceftazidime and ceftaroline against Enterobacteriaceae with extended-spectrum, AmpC, KPC and OXA ß-lactamases. We examined whether similar potentiation was obtained against non-fermenters, which are less permeable than Enterobacteriaceae and have more potent efflux. METHODS: MICs of ceftazidime+NXL104 (with NXL104 at 4 mg/L) and comparators were determined by CLSI agar dilution for: (i) Pseudomonas aeruginosa AmpC mutants and extended-spectrum ß-lactamase (ESBL)-producing transconjugants; (ii) clinical P. aeruginosa isolates with AmpC enzymes, ESBLs or up-regulated efflux; (iii) P. aeruginosa and Burkholderia cepacia complex isolates from cystic fibrosis patients; and (iv) Acinetobacter baumannii with OXA carbapenemases, which also compromise ceftazidime. RESULTS: NXL104 reversed AmpC-mediated ceftazidime resistance in P. aeruginosa, reducing MICs for fully derepressed mutants and isolates to ≤ 8 mg/L. NXL104 also reversed ceftazidime resistance caused by the ESBL PER-1, but not that due to OXA ESBLs or VEB-1 enzyme. Efflux-mediated resistance was unaffected. Resistance to ceftazidime in isolates of P. aeruginosa and the B. cepacia complex from patients with cystic fibrosis was variably overcome, generally to greater effect for B. cepacia. NXL104 had little effect on MICs of ceftazidime for A. baumannii isolates with OXA carbapenemases. CONCLUSIONS: The potentiation of ceftazidime against many ß-lactamase-producing P. aeruginosa and B. cepacia complex strains confirms that NXL104 penetrates these organisms. The utility of the combination against these pathogens will depend on the local prevalence of strains with ß-lactamase- versus efflux-mediated resistance. The lack of potentiation against A. baumannii may reflect failure of NXL104 to penetrate these bacteria to inhibit relevant (OXA-23, -40, -51 and -58) carbapenemases.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/pharmacology , Azabicyclo Compounds/pharmacology , Burkholderia cepacia complex/drug effects , Ceftazidime/pharmacology , Pseudomonas aeruginosa/drug effects , Acinetobacter baumannii/enzymology , Burkholderia cepacia complex/enzymology , Drug Synergism , Humans , Microbial Sensitivity Tests , Pseudomonas aeruginosa/enzymology , beta-Lactamases/biosynthesis
9.
J Biosci Bioeng ; 107(6): 658-61, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19447345

ABSTRACT

Lipase from Burkholderia cepacia strain is one of the most versatile biocatalysts and is used widely in many biotechnological application fields including detergent additives, the resolution of racemic compounds, etc. Based on the known whole genomic information of B. cepacia strain, both ampicillin and kanamycin were added to the TB-T medium to screen B. cepacia complex stains from rhizosphere soil samples. The selected colonies from the modified TB-T medium were then qualitatively determined the ability to produce extracellular lipase on the rhodamine B-olive oil agar plates. A total of 35 lipolytic pseudo-B. cepacia complex strains were isolated and the positive rate of lipolytic bacteria was 65%. Among them, 15 pseudo-B. cepacia complex strains showed tolerance to benzene, n-hexane and n-heptane at concentration of 10% (V/V) and were identified by the recA gene sequence. All of the 14 lipolytic bacteria were identified as B. cepacia complex strains except that the recA gene sequence of one lipolytic bacterium, strain ZMB009, was not obtained.


Subject(s)
Bacterial Proteins/metabolism , Burkholderia cepacia complex/enzymology , Lipase/metabolism , Plants, Edible/microbiology , Soil Microbiology , Solvents/chemistry , Ampicillin/chemistry , Bacterial Typing Techniques , Burkholderia cepacia complex/drug effects , Kanamycin/chemistry , Solvents/pharmacology
10.
Antimicrob Agents Chemother ; 53(3): 876-82, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19075063

ABSTRACT

Chromosomally encoded ss-lactamases from the Burkholderia cepacia complex species (formerly Pseudomonas cepacia) were characterized. Cloning and sequencing identified an Ambler class A ss-lactamase (PenB) from B. cenocepacia. It shares 82% amino acid identity with the PenA ss-lactamases previously identified from B. multivorans 249. Its expression was dependent upon a LysR-type regulatory protein. Its narrow-spectrum hydrolysis activity mostly included penicillins but also included expanded-spectrum cephalosporins and aztreonam at lower levels. In that study, Pen-like ss-lactamases (PenC, PenD, PenE, PenF) that shared 63 to 92% identity with PenB from B. cenocepacia were identified from other Burkholderia species. The corresponding ss-lactamase genes might be used as genetic tools for accurate Burkholderia species identification.


Subject(s)
Burkholderia cepacia complex/enzymology , Burkholderia cepacia complex/genetics , beta-Lactamases/classification , beta-Lactamases/genetics , Alleles , Amino Acid Sequence , Amino Acid Substitution , Base Sequence , Burkholderia cepacia complex/isolation & purification , Burkholderia cepacia complex/metabolism , DNA, Bacterial/genetics , DNA, Bacterial/metabolism , Drug Resistance, Multiple, Bacterial/genetics , Humans , Hydrolysis , Isoelectric Point , Kinetics , Microbial Sensitivity Tests , Molecular Sequence Data , Phylogeny , Plasmids , Sequence Analysis, DNA , Sequence Homology, Amino Acid , beta-Lactamases/isolation & purification , beta-Lactamases/metabolism
11.
J Bacteriol ; 189(24): 9057-65, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17933889

ABSTRACT

Burkholderia cenocepacia is a gram-negative opportunistic pathogen that belongs to the Burkholderia cepacia complex. B. cenocepacia can survive intracellularly within phagocytic cells, and some epidemic strains produce a brown melanin-like pigment that can scavenge free radicals, resulting in the attenuation of the host cell oxidative burst. In this work, we demonstrate that the brown pigment produced by B. cenocepacia C5424 is synthesized from a homogentisate (HGA) precursor. The disruption of BCAL0207 (hppD) by insertional inactivation resulted in loss of pigmentation. Steady-state kinetic analysis of the BCAL0207 gene product demonstrated that it has 4-hydroxyphenylpyruvic acid dioxygenase (HppD) activity. Pigmentation could be restored by complementation providing hppD in trans. The hppD mutant was resistant to paraquat challenge but sensitive to H2O2 and to extracellularly generated superoxide anions. Infection experiments in RAW 264.7 murine macrophages showed that the nonpigmented bacteria colocalized in a dextran-positive vacuole, suggesting that they are being trafficked to the lysosome. In contrast, the wild-type strain did not localize with dextran. Colocalization of the nonpigmented strain with dextran was reduced in the presence of the NADPH oxidase inhibitor diphenyleneiodonium, and also the inducible nitric oxide inhibitor aminoguanidine. Together, these observations suggest that the brown pigment produced by B. cenocepacia C5424 is a pyomelanin synthesized from an HGA intermediate that is capable of protecting the organism from in vitro and in vivo sources of oxidative stress.


Subject(s)
4-Hydroxyphenylpyruvate Dioxygenase/metabolism , Antioxidants/metabolism , Burkholderia cepacia complex/enzymology , Homogentisic Acid/metabolism , Melanins/biosynthesis , 4-Hydroxyphenylpyruvate Dioxygenase/genetics , Animals , Anti-Bacterial Agents/pharmacology , Burkholderia cepacia complex/drug effects , Burkholderia cepacia complex/genetics , Cell Line , Drug Resistance, Bacterial/physiology , Gene Deletion , Genes, Bacterial , Genetic Complementation Test , Hydrogen Peroxide/pharmacology , Lysosomes/microbiology , Macrophages/microbiology , Melanins/genetics , Mice , Mutagenesis, Insertional , Oxidants/pharmacology , Paraquat/pharmacology , Superoxides/pharmacology
12.
Eur J Clin Microbiol Infect Dis ; 26(12): 869-77, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17874328

ABSTRACT

The Burkholderia cepacia complex (Bcc) is a group of ten closely related species associated with life-threatening infection in cystic fibrosis (CF). These bacteria are highly antibiotic resistant, with some strains transmissible, and in a subgroup of patients, they can cause a rapid and fatal necrotising pneumonia. The Bcc organisms produce a range of exoproducts with virulence potential, including exopolysaccharide, proteases and lipases. Many members of the Bcc are also capable of epithelial cell invasion, although the mechanism(s) involved are poorly understood. This study investigates a role for Bcc lipase in epithelial cell invasion by Bcc strains. Lipase activity was measured in eight species of the Bcc. Strains that produced high levels of lipase were predominantly from the B. multivorans and B. cenocepacia species. Pre-treatment of two epithelial cell lines with Bcc lipase significantly increased invasion by two B. multivorans strains and one B. cenocepacia strain and did not affect either plasma membrane or tight junction integrity. Inhibition of Bcc lipase production by the lipase inhibitor Orlistat significantly decreased invasion by both B. multivorans and B. cenocepacia strains in a concentration-dependent manner. This study demonstrates the extent of lipase production across the Bcc and establishes a potential role for lipase in Bcc epithelial cell invasion.


Subject(s)
Bronchi/cytology , Burkholderia cepacia complex/enzymology , Epithelial Cells/microbiology , Lipase/metabolism , Cell Line , Cell Membrane/metabolism , Enzyme Inhibitors/pharmacology , Humans , Lactones/pharmacology , Lipase/antagonists & inhibitors , Orlistat , Tight Junctions/metabolism
13.
Infect Immun ; 75(5): 2451-60, 2007 May.
Article in English | MEDLINE | ID: mdl-17325048

ABSTRACT

Burkholderia cenocepacia is a gram-negative, non-spore-forming bacillus and a member of the Burkholderia cepacia complex. B. cenocepacia can survive intracellularly in phagocytic cells and can produce at least one superoxide dismutase (SOD). The inability of O2- to cross the cytoplasmic membrane, coupled with the periplasmic location of Cu,ZnSODs, suggests that periplasmic SODs protect bacteria from superoxide that has an exogenous origin (for example, when cells are faced with reactive oxygen intermediates generated by host cells in response to infection). In this study, we identified the sodC gene encoding a Cu,ZnSOD in B. cenocepacia and demonstrated that a sodC null mutant was not sensitive to a H2O2, 3-morpholinosydnonimine, or paraquat challenge but was killed by exogenous superoxide generated by the xanthine/xanthine oxidase method. The sodC mutant also exhibited a growth defect in liquid medium compared to the parental strain, which could be complemented in trans. The mutant was killed more rapidly than the parental strain was killed in murine macrophage-like cell line RAW 264.7, but killing was eliminated when macrophages were treated with an NADPH oxidase inhibitor. We also confirmed that SodC is periplasmic and identified the metal cofactor. B. cenocepacia SodC was resistant to inhibition by H2O2 and was unusually resistant to KCN for a Cu,ZnSOD. Together, these observations establish that B. cenocepacia produces a periplasmic Cu,ZnSOD that protects this bacterium from exogenously generated O2- and contributes to intracellular survival of this bacterium in macrophages.


Subject(s)
Burkholderia cepacia complex/enzymology , Macrophages/microbiology , Periplasm/enzymology , Superoxide Dismutase/metabolism , Animals , Burkholderia cepacia complex/drug effects , Burkholderia cepacia complex/genetics , Burkholderia cepacia complex/growth & development , Cell Line , Humans , Mice , Mutation , Oxidative Stress , Potassium Cyanide/pharmacology , Superoxide Dismutase/genetics , Superoxides/pharmacology
14.
Infect Immun ; 75(4): 1679-89, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17220310

ABSTRACT

Burkholderia cenocepacia, a member of the B. cepacia complex, is an opportunistic pathogen that causes serious infections in patients with cystic fibrosis. We identified a six-gene cluster in chromosome 1 encoding a two-component regulatory system (BCAL2831 and BCAL2830) and an HtrA protease (BCAL2829) hypothesized to play a role in the B. cenocepacia stress response. Reverse transcriptase PCR analysis of these six genes confirmed they are cotranscribed and comprise an operon. Genes in this operon, including htrA, were insertionally inactivated by recombination with a newly created suicide plasmid, pGPOmegaTp. Genetic analyses and complementation studies revealed that HtrA(BCAL2829) was required for growth of B. cenocepacia upon exposure to osmotic stress (NaCl or KCl) and thermal stress (44 degrees C). In addition, replacement of the serine residue in the active site with alanine (S245A) and deletion of the HtrA(BCAL2829) PDZ domains demonstrated that these areas are required for protein function. HtrA(BCAL2829) also localizes to the periplasmic compartment, as shown by Western blot analysis and a colicin V reporter assay. Using the rat agar bead model of chronic lung infection, we also demonstrated that inactivation of the htrA gene is associated with a bacterial survival defect in vivo. Together, our data demonstrate that HtrA(BCAL2829) is a virulence factor in B. cenocepacia.


Subject(s)
Adaptation, Physiological , Burkholderia cepacia complex/enzymology , Burkholderia cepacia complex/growth & development , Hot Temperature , Osmotic Pressure , Serine Endopeptidases/physiology , Amino Acid Substitution , Animals , Bacterial Proteins/genetics , Bacterial Proteins/physiology , Binding Sites , Blotting, Western , Burkholderia Infections/microbiology , Burkholderia cepacia complex/genetics , Burkholderia cepacia complex/pathogenicity , Colicins/analysis , Colicins/genetics , Disease Models, Animal , Gene Deletion , Genes, Bacterial , Genetic Complementation Test , Microbial Viability , Mutagenesis, Insertional , Mutagenesis, Site-Directed , Mutation, Missense , Operon , Periplasmic Proteins/analysis , Plasmids/genetics , Pneumonia, Bacterial/microbiology , RNA, Bacterial/biosynthesis , RNA, Messenger/biosynthesis , Rats , Reverse Transcriptase Polymerase Chain Reaction , Sequence Deletion , Serine Endopeptidases/genetics , Transcription, Genetic
15.
Bioprocess Biosyst Eng ; 29(1): 65-71, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16736230

ABSTRACT

Enzymatic modification of starch using long chain fatty acid makes it thermoplastic suitable for a myriad of industrial applications. An industrial lipase preparation produced by Burkholderia cepacia (lipase PS) was used for modification of cassava starch with two acyl donors, lauric acid and palmitic acid. Reactions performed with palmitic acid by liquid-state and microwave esterification gave a degree of substitution (DS) of 62.08% (DS 1.45) and 42.06% (DS 0.98), respectively. Thermogravimetric analysis showed that onset of decomposition is at a higher temperature (above 600 degrees Celsius) for modified starch than the unmodified starch (280 degrees Celsius). Modified starch showed reduction in alpha-amylase digestibility compared to native starch (76.5-18%). Swelling power lowered for modified starch as esterification renders starch more hydrophobic, making it suitable for biomedical applications as materials for bone fixation and replacements, carriers for controlled release of drugs and bioactive agents. Thus enzymatic esterification is ecofriendly.


Subject(s)
Burkholderia cepacia complex/enzymology , Cocos/chemistry , Manihot/chemistry , Microwaves , Starch/chemistry , Esterification/radiation effects , Starch/radiation effects
16.
J Bacteriol ; 187(24): 8247-55, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16321929

ABSTRACT

The distribution of the metalloprotease gene zmpA was determined among strains of the Burkholderia cepacia complex (Bcc). The zmpA gene was present in B. cepacia, B. cenocepacia, B. stabilis, B. ambifaria and B. pyrrocinia but absent from B. multivorans, B. vietnamiensis, B. dolosa, and B. anthina. The presence of zmpA generally correlated with extracellular proteolytic activity with the exception of five strains, which had zmpA but had no detectable proteolytic activity when skim milk agar was used as a substrate (zmpA protease deficient). Western immunoblot experiments with anti-ZmpA antibodies suggest that the zmpA protease-deficient strains do not secrete or accumulate detectable ZmpA. Transcriptional zmpA::lacZ fusions were introduced in selected strains of the Bcc. zmpA::lacZ was expressed in all strains, but expression was generally lower in the zmpA protease-deficient strains than in the zmpA protease-proficient strains. Quantitative reverse transcriptase real-time PCR demonstrated that zmpA protease-deficient strains did express zmpA mRNA, although at various levels. ZmpA has previously been shown to be positively regulated by the CepIR quorum-sensing system. Addition of exogenous AHLs did not restore extracellular protease production to any of the zmpA protease-deficient strains; however, introduction of cepR in trans complemented protease activity in two of five strains. Extracellular proteolytic activity was restored by the presence of zmpA in trans in two of the five strains. These studies suggest that although some strains of the Bcc contain the zmpA gene, multiple factors may influence its expression.


Subject(s)
Bacterial Proteins/biosynthesis , Bacterial Proteins/genetics , Burkholderia cepacia complex/enzymology , Metalloendopeptidases/biosynthesis , Metalloendopeptidases/genetics , 4-Butyrolactone/analogs & derivatives , 4-Butyrolactone/physiology , Animals , Bacterial Proteins/metabolism , Blotting, Western , Burkholderia cepacia complex/chemistry , Burkholderia cepacia complex/genetics , Caseins/metabolism , Gene Expression , Gene Expression Regulation, Bacterial , Genetic Complementation Test , Ligases/genetics , Ligases/metabolism , Metalloendopeptidases/metabolism , Molecular Sequence Data , RNA, Bacterial/analysis , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...